Search results for "Therapeutics"

showing 10 items of 489 documents

Posaconazole against Candida glabrata Isolates with Various Susceptibilities to Fluconazole

2008

ABSTRACT We investigated the in vitro activities of posaconazole (POS), fluconazole (FLC), amphotericin B (AMB), and caspofungin (CAS) against four clinical isolates of Candida glabrata with various susceptibilities to FLC (FLC MICs ranging from 1.0 to >64 μg/ml). POS MICs ranged from ≤0.03 to 0.5 μg/ml; AMB MICs ranged from 0.25 to 2.0 μg/ml, while CAS MICs ranged from 0.03 to 0.25 μg/ml. When FLC MICs increased, so did POS MICs, although we did not observe any isolate with a POS MIC greater than 0.5 μg/ml. Time-kill experiments showed that POS, FLC, and CAS were fungistatic against all isolates, while AMB at eight times the MIC was fungicidal against three out of four isolates of C. gl…

MalePosaconazoleAntifungal AgentsCandida glabrataMicrobial Sensitivity TestsDrug resistanceBiologyKidneyMicrobiologyMicechemistry.chemical_compoundDrug Resistance Fungalhemic and lymphatic diseasesAmphotericin BmedicineAnimalsHumansExperimental TherapeuticsPharmacology (medical)FluconazolePharmacologyCandida glabrataExperimental modelCandidiasisFungi imperfectiTriazolesbiology.organism_classificationTreatment OutcomeInfectious DiseaseschemistryCaspofunginFluconazolemedicine.drugAntimicrobial Agents and Chemotherapy
researchProduct

Pre-clinical assessment of a water-in-fluorocarbon emulsion for the treatment of pulmonary vascular diseases

2019

Abstract Hypoxic pulmonary vasoconstriction (HPV) is a well-characterized vascular response to low oxygen pressures and is involved in life-threatening conditions such as high-altitude pulmonary edema (HAPE) and pulmonary arterial hypertension (PAH). While the efficacy of oral therapies can be affected by drug metabolism, or dose-limiting systemic toxicity, inhaled treatment via pressured metered dose inhalers (pMDI) may be an effective, nontoxic, practical alternative. We hypothesized that a stable water-in-perfluorooctyl bromide (PFOB) emulsion that provides solubility in common pMDI propellants, engineered for intrapulmonary delivery of pulmonary vasodilators, reverses HPV during acute h…

MalePulmonary CirculationDrug Evaluation PreclinicalPharmaceutical Science02 engineering and technologyPharmacology030226 pharmacology & pharmacyRats Sprague-DawleyDrug Delivery Systems0302 clinical medicineHypoxic pulmonary vasoconstrictionHigh-altitude pulmonary edemapulmonary hypertensionMedicineFluorocarbonsPhenylpropionatesmedicine.diagnostic_testGeneral Medicine021001 nanoscience & nanotechnologyPulmonary edema3. Good healthPyridazinesTreatment Outcomemedicine.anatomical_structureEmulsions0210 nano-technologyendothelinResearch Articlemedicine.drugpulmonary pressuresAmbrisentanambrisentanHypertension PulmonaryPulmonary Edema03 medical and health sciencesmedicine.arteryAnimalsAntihypertensive AgentsLungsodium nitriteperfluorocarbonbusiness.industrylcsh:RM1-950Watermedicine.diseasePulmonary hypertensionRatsBronchoalveolar lavagelcsh:Therapeutics. PharmacologyPulmonary arteryhigh altitude pulmonary edemabusinessDrug Delivery
researchProduct

Posaconazole Activity against Candida glabrata after Exposure to Caspofungin or Amphotericin B

2008

ABSTRACT We evaluated the effects of sequential therapy with caspofungin (CAS) or amphotericin B (AMB) followed by posaconazole (POS) against Candida glabrata . The susceptibilities to POS of yeast cells pre-exposed to CAS or AMB were identical to those of untreated cells as shown by standard Clinical and Laboratory Standards Institute broth dilution, cell viability, and disk diffusion methods. We then investigated the activity of sequential regimens in an experimental model of disseminated candidiasis. CAS given at 1 mg/kg/day for 2 days followed by POS at either 15 or 30 mg/kg/day significantly reduced the counts compared to the controls, but this treatment was not superior to the use of …

MaleSettore MED/07 - Microbiologia E Microbiologia ClinicaPosaconazoleAntifungal Agentsmedicine.drug_classAntibioticsColony Count MicrobialCandida glabrataMicrobial Sensitivity TestsBiologyPharmacologyKidneyDrug Administration ScheduleMicrobiologyEchinocandinsLipopeptidesMicechemistry.chemical_compoundCaspofunginAmphotericin BAmphotericin BmedicineAnimalsHumansExperimental TherapeuticsPharmacology (medical)Viability assayPharmacologyCandida glabrataPosaconazole Candida glabrataCandidiasisTriazolesbacterial infections and mycosesbiology.organism_classificationDisseminated CandidiasisRegimenTreatment OutcomeInfectious DiseaseschemistryCaspofunginmedicine.drugAntimicrobial Agents and Chemotherapy
researchProduct

White blood cell counts as risk markers of developing metabolic syndrome and its components in the Predimed study.

2013

Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; TRIAL REGISTRATION Controlled-Trials.comISRCTN35739639. BACKGROUND The Metabolic Syndrome (MetS) is a cluster of metabolic abnormalities that includes hyperglucemia, hypertension, dyslipidemia and central obesity, conferring an increased risk of cardiovascular disease. The white blood cell (WBC) count has been proposed as a marker for predicting cardiovascular risk. However, few prospective studies have evaluated the relationship between WBC subtypes and risk of MetS. METHODS Participants were recruited from seven PREDIMED study centers. Both a baseline cross-sectional (n = 4,377) and a prospe…

MaleSíndrome metabòlicaMediterranean dietNeutrophilsEpidemiologyEstudios transversalesMetabolic disorders:Named Groups::Persons::Age Groups::Adult::Aged::Aged 80 and over [Medical Subject Headings]Disease:Named Groups::Persons::Age Groups::Adult::Middle Aged [Medical Subject Headings]Diet Mediterranean:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Probability::Risk::Risk Factors [Medical Subject Headings]:Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings]Leukocyte CountLymphocitesRisk FactorsBlood plasmaPathologyMedicineProspective StudiesProspective cohort studyAged 80 and overMetabolic SyndromeClinical ChemistryMultidisciplinary:Analytical Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Nutrition Therapy::Diet Therapy::Diet Mediterranean [Medical Subject Headings]QRMiddle AgedMetabolic syndromeClinical Laboratory Sciences1932-6203:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cross-Sectional Studies [Medical Subject Headings]medicine.anatomical_structureCholesterolCardiovascular diseasesCardiovascular DiseasesMedicineWhite blood cellsFemalePublic HealthEnfermedades cardiovascularesResearch Articlemedicine.medical_specialty:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cohort Studies::Longitudinal Studies::Prospective Studies [Medical Subject Headings]Recuento de linfocitosScience:Check Tags::Male [Medical Subject Headings]Mediterranean cookingDiagnostic MedicineInternal medicineWhite blood cell:Analytical Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Diagnostic Techniques and Procedures::Clinical Laboratory Techniques::Cytological Techniques::Cell Count::Blood Cell Count::Leukocyte Count::Lymphocyte Count [Medical Subject Headings]Cuina mediterràniaHumansLymphocyte CountObesity:Named Groups::Persons::Age Groups::Adult::Aged [Medical Subject Headings]:Diseases::Cardiovascular Diseases [Medical Subject Headings]Cardiovascular Disease EpidemiologyAged:Diseases::Nutritional and Metabolic Diseases::Metabolic Diseases::Metabolic Syndrome X [Medical Subject Headings]business.industryMalalties cardiovascularsRecuento de leucocitosSíndrome X metabólicomedicine.diseaseObesityLong-Term CareDieta mediterránea:Analytical Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Diagnostic Techniques and Procedures::Clinical Laboratory Techniques::Cytological Techniques::Cell Count::Blood Cell Count::Leukocyte Count [Medical Subject Headings]Biomarker EpidemiologyCross-Sectional Studies:Check Tags::Female [Medical Subject Headings]GeriatricsImmunologyClinical ImmunologyPreventive MedicineMetabolic syndrome:Anatomy::Cells::Blood Cells::Leukocytes::Granulocytes::Neutrophils [Medical Subject Headings]businessDyslipidemiaBiomarkersGeneral Pathology
researchProduct

Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available s…

2015

Edward M Wolin,1 Barbara Jarzab,2 Barbro Eriksson,3 Thomas Walter,4 Christos Toumpanakis,5 Michael A Morse,6 Paola Tomassetti,7 Matthias M Weber,8 David R Fogelman,9 John Ramage,10 Donald Poon,11 Brian Gadbaw,12 Jiang Li,12 Janice L Pasieka,13 Abakar Mahamat,14 Fredrik Swahn,15 John Newell-Price,16 Wasat Mansoor,17 Kjell Öberg3 1Markey Cancer Center, University of Kentucky, Lexington, KY, USA; 2Department of Nuclear Medicine and Endocrine Oncology, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice, Poland; 3Department of Medical Sciences, Endocrine Oncology Unit, University Hospital, Uppsala, Sweden; 4Department of Medical Oncology, Ed…

MaleTime FactorsPharmaceutical ScienceOctreotideKaplan-Meier EstimateNeuroendocrine tumorsDigestive System NeoplasmsOctreotideGastroenterologychemistry.chemical_compoundDrug DiscoveryOdds RatioOriginal ResearchAged 80 and oversomatostatin analoguesDrug SubstitutionHazard ratioMiddle AgedTumor BurdenTreatment OutcomeFemalemedicine.symptomSomatostatinCarcinoid syndromemedicine.drugAdultmedicine.medical_specialtyNauseaCarcinoid tumorscarcinoid syndromeAntineoplastic AgentsCarcinoid TumorDisease-Free SurvivalDouble-Blind MethodInternal medicinemedicineHumansProgression-free survivalAgedProportional Hazards ModelsPharmacologypasireotideCancer och onkologiDrug Design Development and Therapybusiness.industrylcsh:RM1-950medicine.diseasesymptom controlPasireotidelcsh:Therapeutics. PharmacologyEndocrinologyLogistic ModelschemistryDrug Resistance NeoplasmDelayed-Action PreparationsCancer and Oncologyneuroendocrine tumorsbusinessprogression-free survival
researchProduct

Umbilical cord blood transplantation from unrelated donors in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia

2014

Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; There are very few disease-specific studies focusing on outcomes of umbilical cord blood transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia. We report the outcome of 45 patients with Philadelphia chromosome-positive acute lymphoblastic leukemia who underwent myeloablative single unit cord blood transplantation from unrelated donors within the GETH/GITMO cooperative group. Conditioning regimens were based on combinations of thiotepa, busulfan, cyclophospamide or fludarabine, and antithymocyte globulin. At the time of transplantation, 35 patients (78%) were in first complete remission, four (8%) …

MaleTransplantation Conditioning:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Case-Control Studies::Retrospective Studies [Medical Subject Headings]Leucemia-linfoma linfoblástico de células precursorasGraft vs Host Disease:Named Groups::Persons::Age Groups::Adult::Middle Aged [Medical Subject Headings]Supervivencia sin EnfermedadGastroenterology:Anatomy::Body Regions::Transplants::Allografts [Medical Subject Headings]:Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents::Myeloablative Agonists [Medical Subject Headings]:Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings]hemic and lymphatic diseasesMedicineCumulative incidenceTasa de SupervivenciaPhiladelphia ChromosomeChildCromosoma Filadelfia:Diseases::Pathological Conditions Signs and Symptoms::Pathologic Processes::Disease Attributes::Chronic Disease [Medical Subject Headings]:Named Groups::Persons::Age Groups::Child::Child Preschool [Medical Subject Headings]ArticlesHematologyMiddle AgedPrecursor Cell Lymphoblastic Leukemia-LymphomaAllografts:Analytical Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Biological Therapy::Immunomodulation::Immunotherapy::Immunosuppression::Transplantation Conditioning [Medical Subject Headings]FludarabineSurvival RateChild Preschool:Named Groups::Persons::Age Groups::Adolescent [Medical Subject Headings]:Diseases::Pathological Conditions Signs and Symptoms::Pathologic Processes::Chromosome Aberrations::Translocation Genetic::Philadelphia Chromosome [Medical Subject Headings]:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Survival Analysis::Disease-Free Survival [Medical Subject Headings]FemaleAcondicionamiento para el trasplanteCord Blood Stem Cell TransplantationTrasplante de células madre de la sangre del cordónmedicine.drugAloinjertosAdultmedicine.medical_specialtyAdolescent:Check Tags::Male [Medical Subject Headings]Cord Blood Stem Cell TransplantationPhiladelphia chromosomeEnfermedad injerto contra huéspedDisease-Free SurvivalEstudios retrospectivosInternal medicine:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cohort Studies::Longitudinal Studies::Follow-Up Studies [Medical Subject Headings]:Named Groups::Persons::Age Groups::Adult [Medical Subject Headings]HumansPreschoolSurvival rate:Named Groups::Persons::Age Groups::Child [Medical Subject Headings]Retrospective Studies:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Data Collection::Vital Statistics::Mortality::Survival Rate [Medical Subject Headings]business.industryUmbilical Cord Blood TransplantationEnfermedad crónicaAgonistas mieloablativosMyeloablative Agonistsmedicine.diseaseSettore MED/15SurgeryTransplantation:Diseases::Immune System Diseases::Graft vs Host Disease [Medical Subject Headings]:Diseases::Hemic and Lymphatic Diseases::Lymphatic Diseases::Lymphoproliferative Disorders::Leukemia Lymphoid::Precursor Cell Lymphoblastic Leukemia-Lymphoma [Medical Subject Headings]:Check Tags::Female [Medical Subject Headings]Estudios de SeguimientoChronic Disease:Analytical Diagnostic and Therapeutic Techniques and Equipment::Surgical Procedures Operative::Transplantation::Cell Transplantation::Stem Cell Transplantation::Cord Blood Stem Cell Transplantation [Medical Subject Headings]Adolescent; Adult; Allografts; Child; Child Preschool; Chronic Disease; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Disease; Humans; Male; Middle Aged; Myeloablative Agonists; Retrospective Studies; Survival Rate; Cord Blood Stem Cell Transplantation; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Transplantation ConditioningbusinessBusulfanFollow-Up Studies
researchProduct

Sociodemographic Factors and Clinical Conditions Associated to Hospitalization in Influenza A (H1N1) 2009 Virus Infected Patients in Spain, 2009–2010

2012

The emergence and pandemic spread of a new strain of influenza A (H1N1) virus in 2009 resulted in a serious alarm in clinical and public health services all over the world. One distinguishing feature of this new influenza pandemic was the different profile of hospitalized patients compared to those from traditional seasonal influenza infections. Our goal was to analyze sociodemographic and clinical factors associated to hospitalization following infection by influenza A(H1N1) virus. We report the results of a Spanish nationwide study with laboratory confirmed infection by the new pandemic virus in a case-control design based on hospitalized patients. The main risk factors for hospitalizatio…

MaleViral DiseasesPediatricsNon-Clinical MedicinePulmonologyEpidemiology:Named Groups::Persons::Age Groups::Adult::Aged::Aged 80 and over [Medical Subject Headings]Grip A (H1N1):Named Groups::Persons::Age Groups::Adult::Middle Aged [Medical Subject Headings]DiseaseSocial and Behavioral Sciencesmedicine.disease_cause:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Probability::Risk::Risk Factors [Medical Subject Headings]Hospital patients:Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings]Influenza A Virus H1N1 SubtypeGripe humanaSociologyRisk FactorsPandemicInfluenza A virusChildAged 80 and over:Geographicals::Geographic Locations::Europe::Spain [Medical Subject Headings]:Organisms::Viruses::Vertebrate Viruses::RNA Viruses::Orthomyxoviridae::Influenzavirus A::Influenza A virus::Influenza A Virus H1N1 Subtype [Medical Subject Headings]COPDeducation.field_of_studyMultidisciplinary:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Case-Control Studies [Medical Subject Headings]:Named Groups::Persons::Age Groups::Child::Child Preschool [Medical Subject Headings]QRMiddle AgedHospitalizationInfectious Diseases:Analytical Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Patient Care::Hospitalization [Medical Subject Headings]Child Preschool:Named Groups::Persons::Age Groups::Adolescent [Medical Subject Headings]MedicineFemalePublic Health:Named Groups::Persons::Age Groups::Infant [Medical Subject Headings]Assistència hospitalàriaResearch ArticleAdultmedicine.medical_specialtyAdolescent:Named Groups::Persons::Age Groups::Adult::Young Adult [Medical Subject Headings]SciencePopulationHospitals -- Pacients:Check Tags::Male [Medical Subject Headings]:Named Groups::Persons::Age Groups::Infant::Infant Newborn [Medical Subject Headings]InfluenzavirusVirusYoung AdultInfluenza HumanSubtipo H1N1 del Virus de la Influenza A:Named Groups::Persons::Age Groups::Adult [Medical Subject Headings]medicineInfluenza virusesHumansEpidemiologia -- Investigació -- EspanyaEspanyaEpidemiologiaeducationPandemicsBiology:Named Groups::Persons::Age Groups::Child [Medical Subject Headings]AgedHospital carePopulation Biologybusiness.industryPublic healthInfant NewbornCase-control studyInfant:Health Care::Environment and Public Health::Public Health::Disease Outbreaks::Epidemics::Pandemics [Medical Subject Headings]medicine.disease:Check Tags::Female [Medical Subject Headings]SpainCase-Control StudiesH1N1 influenza:Diseases::Virus Diseases::RNA Virus Infections::Orthomyxoviridae Infections::Influenza Human [Medical Subject Headings]businessPLoS ONE
researchProduct

Prognostic Impact of Hyponatremia and Hypernatremia in COVID-19 Pneumonia. A HOPE-COVID-19 (Health Outcome Predictive Evaluation for COVID-19) Regist…

2020

Dysnatremia is associated with increased mortality in patients with community-acquired pneumonia. SARS-COV2 (Severe-acute-respiratory syndrome caused by Coronavirus-type 2) pneumonia can be fatal. The aim of this study was to ascertain whether admittance dysnatremia is associated with mortality, sepsis, or intensive therapy (IT) in patients hospitalized with SARS-COV2 pneumonia. This is a retrospective study of the HOPE-COVID-19 registry, with data collected from January 1th through April 31th, 2020. We selected all hospitalized adult patients with RT-PCR-confirmed SARS-COV2 pneumonia and a registered admission serum sodium level (SNa). Patients were classified as hyponatremic (SNa <…

MalehyponatremiaEndocrinology Diabetes and Metabolism030204 cardiovascular system & hematologyGlobal Healthlcsh:Diseases of the endocrine glands. Clinical endocrinology:Health Care::Health Care Quality Access and Evaluation::Quality of Health Care::Health Care Evaluation Mechanisms::Outcome and Process Assessment (Health Care) [Medical Subject Headings]:Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings]sepsis0302 clinical medicineEndocrinology:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cohort Studies::Retrospective Studies [Medical Subject Headings]HiponatremiaOutcome Assessment Health CareSARS-COV2Hospital MortalityRegistriesOriginal Research:Persons::Persons::Age Groups::Adult::Aged [Medical Subject Headings]:Health Care::Environment and Public Health::Public Health::Epidemiologic Methods::Data Collection::Registries [Medical Subject Headings]HypernatremiahypernatremiaMiddle AgedPrognosisVirusHospitalizationSurvival Rate:Analytical Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Patient Care::Hospitalization [Medical Subject Headings]HipernatremiaFemaleHyponatremiaHyponatremiamedicine.medical_specialty:Information Science::Information Science::Data Collection::Vital Statistics::Mortality::Survival Rate [Medical Subject Headings]Coronavirus disease 2019 (COVID-19)Infecciones por coronavirus:Check Tags::Male [Medical Subject Headings]030209 endocrinology & metabolismSepsis03 medical and health sciencesInternal medicineSepsis:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cohort Studies::Longitudinal Studies::Follow-Up Studies [Medical Subject Headings]medicineHumans:Diseases::Nutritional and Metabolic Diseases::Metabolic Diseases::Water-Electrolyte Imbalance::Hypernatremia [Medical Subject Headings]MortalitySurvival rateAgedRetrospective Studieslcsh:RC648-665business.industrySARS-CoV-2COVID-19Retrospective cohort study:Persons::Persons::Age Groups::Adult::Middle Aged [Medical Subject Headings]Aparato respiratoriomedicine.diseasemortality:Diseases::Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [Medical Subject Headings]Clinical trialbody regionsPneumonia:Check Tags::Female [Medical Subject Headings]:Diseases::Nutritional and Metabolic Diseases::Metabolic Diseases::Water-Electrolyte Imbalance::Hyponatremia [Medical Subject Headings]Mortalidad:Analytical Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Prognosis [Medical Subject Headings]:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Data Collection::Vital Statistics::Mortality::Hospital Mortality [Medical Subject Headings]HypernatremiabusinessFollow-Up Studies
researchProduct

Phase II dose escalation study of caspofungin for invasive Aspergillosis.

2011

ABSTRACT Our objective was to evaluate the maximum tolerated dose of caspofungin for invasive aspergillosis (IA). The safety and pharmacokinetics of escalating dosages of caspofungin were investigated in IA. Eight patients each received caspofungin 70, 100, 150, or 200 mg once a day (QD). Dose-limiting toxicity (DLT) was defined as the same non-hematological treatment-related adverse event of grade ≥4 in 2 of 8 patients or ≥3 in 4 of 8 patients in a cohort. A total of 46 patients (median age, 61 years; 21 female; 89% with hematological malignancies) received caspofungin (9, 8, 9, and 20 patients in the 70-, 100-, 150-, and 200-mg cohorts) for a median of 24.5 days. Plasma pharmacokinetics w…

Malemedicine.medical_specialtyAntifungal AgentsDoseBiologyPharmacologyClinical TherapeuticsAspergillosisGastroenterologyDrug Administration ScheduleCohort Studieschemistry.chemical_compoundEchinocandinsLipopeptidesPharmacokineticsCaspofunginInternal medicinemedicineAspergillosisHumansPharmacology (medical)PharmacologyVoriconazoleVolume of distributionDose-Response Relationship DrugLiterMiddle Agedmedicine.diseaseSurvival AnalysisInfectious DiseasesTreatment OutcomechemistryToxicityFemaleCaspofunginmedicine.drugFollow-Up StudiesAntimicrobial agents and chemotherapy
researchProduct

Upregulation of Phospholipase D Expression and Activation in Ventricular Pressure-Overload Hypertrophy

2005

Evidence for a role of phospholipase D (PLD) in cellular proliferation and differentiation is accumulating. We studied PLD activity and expression in normal and hypertrophic rat and human hearts. In rat heart, abdominal aortic banding (constriction to 50% of original lumen) caused hypertrophy in the left ventricle (as shown by weight index and ANP expression) by about 15% after 30 days without histological evidence of fibrosis or signs of decompensation and in the right ventricle after 100 days. The hypertrophy was accompanied by small increases of basal PLD activity and strong potentiation of stimulated PLD activity caused by 4β-phorbol-12β,13α-dibutyrate (PDB) and by phenylephrine. The mR…

Malemedicine.medical_specialtyBlotting WesternCardiomegalyBiologyGene Expression Regulation EnzymologicMuscle hypertrophyRats Sprague-DawleyDownregulation and upregulationInternal medicinePhospholipase DVentricular PressuremedicineAnimalsHumansRNA MessengerPhenylephrineProtein Kinase CProtein kinase CPharmacologyReverse Transcriptase Polymerase Chain ReactionPhospholipase DPLD2lcsh:RM1-950Body WeightRatsReceptors AdrenergicUp-RegulationEnzyme ActivationIsoenzymeslcsh:Therapeutics. Pharmacologymedicine.anatomical_structureEndocrinologyVentricleVentricular pressureMolecular Medicinelipids (amino acids peptides and proteins)Signal Transductionmedicine.drugJournal of Pharmacological Sciences
researchProduct